DNA RNA and Cells

13 Jan 2020 Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area
13 Jan 2020 Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
12 Jan 2020 LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome
12 Jan 2020 LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
12 Jan 2020 Announcement of iPSC Derived Gene-modified NK Cell Development Targeting Solid Tumors
12 Jan 2020 PACT Pharma Raises $75M in Oversubscribed Series C Financing to Develop Fully Personalized NeoTCR-T Cell Therapies for Patients with Cancer
12 Jan 2020 Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study
12 Jan 2020 Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
12 Jan 2020 Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy
12 Jan 2020 Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
12 Jan 2020 Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
09 Jan 2020 Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis (BEAT-MS) Begins Enrollment
09 Jan 2020 Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR™ Therapy for Relapsed or Refractory T-cell Malignancies
09 Jan 2020 Locus Biosciences initiates world's first controlled clinical trial for a CRISPR enhanced bacteriophage therapy
09 Jan 2020 Finch Therapeutics Completes Enrollment in Potentially Pivotal Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection
08 Jan 2020 Promethera announces Initiation of Phase 2b DHELIVER Study of HepaStem™ in patients with Acute-on-Chronic Liver Failure (ACLF)
06 Jan 2020 Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer
03 Jan 2020 BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science
02 Jan 2020 Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of Omidubicel
30 Dec 2019 Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease
26 Dec 2019 Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease
23 Dec 2019 BioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A
23 Dec 2019 Urovant Sciences Initiates Patient Enrollment in Phase 2a Study of URO-902
21 Dec 2019 Longeveron LLC Announces Completion of Enrollment in Phase 1 Clinical Trial of Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) in Alzheimer's Disease
21 Dec 2019 Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up